Heron Therapeutics is positioning its drug, Zynrelef, as a way to help patients avoid addictive opioid painkillers following surgery. The extended-release formulation offers analgesic effects over 72 hours—when postsurgical pain is most severe and more likely to require pain management medication.
Dubbed iovera, MyoScience's technology received FDA clearance in 2017 for treating the pain associated with osteoarthritis after knee replacement surgery.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
What if local anesthesia didn't wear off after surgery? Or at least not for three or four days. That's a concept San Diego's Heron Therapeutics is moving into Phase 3 trials this year, with its long-acting and potentially opioid-sparing formulation.